drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB01168 | DB09351 | 1,053 | 722 | [
"DDInter1526",
"DDInter1048"
] | Procarbazine | Levobetaxolol (ophthalmic) | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | (S)-betaxolol is the (S)-enantiomer of betaxolol. It is an enantiomer of a (R)-betaxolol. | Moderate | 1 | [
[
[
1053,
24,
722
]
],
[
[
1053,
64,
770
],
[
770,
24,
722
]
],
[
[
1053,
25,
1011
],
[
1011,
24,
722
]
],
[
[
1053,
64,
770
],
[
770,
... | [
[
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levobetaxolol"
]
],
[
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Th... | Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Levobetaxolol
Procarbazine may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Levobetaxolol
Procarbazine ... |
DB00554 | DB01234 | 1,027 | 1,220 | [
"DDInter1478",
"DDInter513"
] | Piroxicam | Dexamethasone | A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily. | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Moderate | 1 | [
[
[
1027,
24,
1220
]
],
[
[
1027,
24,
870
],
[
870,
1,
1220
]
],
[
[
1027,
24,
175
],
[
175,
40,
1220
]
],
[
[
1027,
63,
251
],
[
251,
... | [
[
[
"Piroxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
],
[
[
"Piroxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
... | Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Dexamethasone (Compound)
Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Dexam... |
DB01254 | DB06176 | 1,213 | 1,342 | [
"DDInter484",
"DDInter1616"
] | Dasatinib | Romidepsin | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Moderate | 1 | [
[
[
1213,
24,
1342
]
],
[
[
1213,
62,
1247
],
[
1247,
23,
1342
]
],
[
[
1213,
63,
336
],
[
336,
24,
1342
]
],
[
[
1213,
24,
1616
],
[
1616... | [
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Dasatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
... | Dasatinib may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Romidepsin
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and ... |
DB00773 | DB08880 | 896 | 1,510 | [
"DDInter702",
"DDInter1771"
] | Etoposide | Teriflunomide | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitoti... | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Major | 2 | [
[
[
896,
25,
1510
]
],
[
[
896,
63,
1461
],
[
1461,
23,
1510
]
],
[
[
896,
24,
129
],
[
129,
63,
1510
]
],
[
[
896,
24,
1136
],
[
1136,
... | [
[
[
"Etoposide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E"... | Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Teriflunomide
Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalut... |
DB01050 | DB09122 | 848 | 1,613 | [
"DDInter900",
"DDInter1409"
] | Ibuprofen | Peginterferon beta-1a | Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally p... | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years... | Moderate | 1 | [
[
[
848,
24,
1613
]
],
[
[
848,
24,
1627
],
[
1627,
24,
1613
]
],
[
[
848,
63,
152
],
[
152,
24,
1613
]
],
[
[
848,
74,
1274
],
[
1274,
... | [
[
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
]... | Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Bosentan a... |
DB00563 | DB00710 | 663 | 1,199 | [
"DDInter1174",
"DDInter897"
] | Methotrexate | Ibandronate | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Ibandronate, or BM 21.0955, is a third generation, nitrogen containing bisphosphonate similar to [zoledronic acid], [minodronic acid], and [risedronic acid].[A203111,A203138] It is used to prevent and treat postmenopausal osteoporosis.[L13805,L13808] Ibandronate was first described in the literature in 1993 as a treatm... | Moderate | 1 | [
[
[
663,
24,
1199
]
],
[
[
663,
63,
963
],
[
963,
1,
1199
]
],
[
[
663,
21,
28719
],
[
28719,
60,
1199
]
],
[
[
663,
63,
1555
],
[
1555,
... | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibandronate"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zoledronic acid"
]... | Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Zoledronic acid and Zoledronic acid (Compound) resembles Ibandronate (Compound)
Methotrexate (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Ibandronate (Compound)
Methotrexate may cause a moderate inte... |
DB00653 | DB09237 | 544 | 1,586 | [
"DDInter1120",
"DDInter1045"
] | Magnesium sulfate | Levamlodipine | A small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions... | Levamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of [amlodipine], an antihypertensive medication. Levamlodipine belongs to the dihydropyridine group of calcium channel blockers. This medication was first marketed in Russia and India before being granted FDA approval. The names S-amlod... | Moderate | 1 | [
[
[
544,
24,
1586
]
],
[
[
544,
24,
870
],
[
870,
24,
1586
]
],
[
[
544,
63,
251
],
[
251,
24,
1586
]
],
[
[
544,
24,
1019
],
[
1019,
... | [
[
[
"Magnesium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levamlodipine"
]
],
[
[
"Magnesium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocort... | Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine
Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken... |
DB00620 | DB00930 | 175 | 166 | [
"DDInter1855",
"DDInter432"
] | Triamcinolone | Colesevelam | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermat... | Colesevelam is a bile acid sequestrant. Colesevelam is used with exercise and diet changes (restriction of cholesterol and fat intake) to reduce the amount of cholesterol and certain fatty substances in the blood. It works by binding bile acids in the intestine. Bile acids are made when cholesterol is broken down in th... | Moderate | 1 | [
[
[
175,
24,
166
]
],
[
[
175,
24,
959
],
[
959,
63,
166
]
],
[
[
175,
63,
1645
],
[
1645,
24,
166
]
],
[
[
175,
24,
126
],
[
126,
2... | [
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Colesevelam"
]
],
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
... | Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Colesevelam
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Me... |
DB00209 | DB00777 | 352 | 146 | [
"DDInter1886",
"DDInter1537"
] | Trospium | Propiomazine | Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably. An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination. Trospium is manufactured by _Indevu... | Propiomazine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia. Future uses may include the treatment of obsessive-compulsive disorder and severe behavioral disorders in autism. Struct... | Moderate | 1 | [
[
[
352,
24,
146
]
],
[
[
352,
24,
508
],
[
508,
1,
146
]
],
[
[
352,
24,
401
],
[
401,
63,
146
]
],
[
[
352,
24,
1301
],
[
1301,
40... | [
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomazine"
]
],
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
],
[
... | Trospium may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Propiomazine (Compound)
Trospium may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could... |
DB00213 | DB00277 | 837 | 1,031 | [
"DDInter1388",
"DDInter1791"
] | Pantoprazole | Theophylline | Pantoprazole is a first-generation proton pump inhibitor (PPI) used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zolling... | A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under seve... | Moderate | 1 | [
[
[
837,
24,
1031
]
],
[
[
837,
6,
6017
],
[
6017,
45,
1031
]
],
[
[
837,
21,
28666
],
[
28666,
60,
1031
]
],
[
[
837,
25,
915
],
[
915,
... | [
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Theophylline"
]
],
[
[
"Pantoprazole",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compo... | Pantoprazole (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Theophylline (Compound)
Pantoprazole (Compound) causes Nervous system disorder (Side Effect) and Nervous system disorder (Side Effect) is caused by Theophylline (Compound)
Pantoprazole may lead to a major life threatening interaction when taken w... |
DB00835 | DB01075 | 100 | 1,376 | [
"DDInter245",
"DDInter569"
] | Brompheniramine | Diphenhydramine | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnoti... | Moderate | 1 | [
[
[
100,
35,
1376
]
],
[
[
100,
24,
649
],
[
649,
63,
1376
]
],
[
[
100,
63,
128
],
[
128,
24,
1376
]
],
[
[
100,
1,
11786
],
[
11786,
... | [
[
[
"Brompheniramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
]
],
[
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseas... | Brompheniramine (Compound) resembles Diphenhydramine (Compound) and
Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Brompheniramine may cause a modera... |
DB04868 | DB09049 | 478 | 1,135 | [
"DDInter1293",
"DDInter1261"
] | Nilotinib | Naloxegol | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. The advantage of naloxegol over the opioid antag... | Minor | 0 | [
[
[
478,
23,
1135
]
],
[
[
478,
24,
807
],
[
807,
23,
1135
]
],
[
[
478,
64,
33
],
[
33,
23,
1135
]
],
[
[
478,
25,
495
],
[
495,
23... | [
[
[
"Nilotinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
]
],
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ulipristal"
],
[
"... | Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ulipristal and Ulipristal may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Nilotinib may lead to a major life threatening interaction when taken with Amiodarone and Amiodarone may cause a min... |
DB00444 | DB10276 | 63 | 1,624 | [
"DDInter1765",
"DDInter1623"
] | Teniposide | Rotavirus vaccine | Teniposide is a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells ... | Rotavirus commonly infects children and infants causing severe diarrhea and vomiting leading to potentially fatal dehydration. Two rotavirus vaccines are available for the prevention of rotavirus gastroenteritis, Rotateq and Rotarix. Rotateq is a live vaccine consisting of 5 reassorted human-bovine viral strains. Rotar... | Major | 2 | [
[
[
63,
25,
1624
]
],
[
[
63,
25,
770
],
[
770,
25,
1624
]
],
[
[
63,
24,
1480
],
[
1480,
25,
1624
]
],
[
[
63,
63,
58
],
[
58,
25,
... | [
[
[
"Teniposide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Teniposide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
... | Teniposide may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Rotavirus vaccine
Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may lead to a major ... |
DB00472 | DB00712 | 758 | 1,274 | [
"DDInter758",
"DDInter763"
] | Fluoxetine | Flurbiprofen | Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies. | Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically p... | Moderate | 1 | [
[
[
758,
24,
1274
]
],
[
[
758,
6,
1829
],
[
1829,
45,
1274
]
],
[
[
758,
18,
3965
],
[
3965,
57,
1274
]
],
[
[
758,
21,
28769
],
[
28769,... | [
[
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
]
],
[
[
"Fluoxetine",
"{u} (Compound) binds {v} (Gene)",
"ALB"
],
[
"ALB",
"{u} (Gene) is bound by {v} (Compound)",
... | Fluoxetine (Compound) binds ALB (Gene) and ALB (Gene) is bound by Flurbiprofen (Compound)
Fluoxetine (Compound) downregulates MRPS2 (Gene) and MRPS2 (Gene) is downregulated by Flurbiprofen (Compound)
Fluoxetine (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Flurbiprofen... |
DB00927 | DB11718 | 1,559 | 927 | [
"DDInter712",
"DDInter640"
] | Famotidine | Encorafenib | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</su... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Moderate | 1 | [
[
[
1559,
24,
927
]
],
[
[
1559,
62,
112
],
[
112,
23,
927
]
],
[
[
1559,
23,
1247
],
[
1247,
23,
927
]
],
[
[
1559,
63,
216
],
[
216,
... | [
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Famotidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Famotidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Famotidine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and... |
DB00574 | DB04855 | 121 | 540 | [
"DDInter717",
"DDInter602"
] | Fenfluramine | Dronedarone | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients ty... | Dronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primarily focuses on stroke prevention and symptom management. It is managed by rate contro... | Moderate | 1 | [
[
[
121,
24,
540
]
],
[
[
121,
24,
473
],
[
473,
24,
540
]
],
[
[
121,
24,
144
],
[
144,
63,
540
]
],
[
[
121,
64,
506
],
[
506,
24,... | [
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronedarone"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
],
... | Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Dronedarone
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol and... |
DB00738 | DB01362 | 485 | 497 | [
"DDInter1420",
"DDInter960"
] | Pentamidine | Iohexol | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. | Major | 2 | [
[
[
485,
25,
497
]
],
[
[
485,
25,
258
],
[
258,
40,
497
]
],
[
[
485,
21,
28681
],
[
28681,
60,
497
]
],
[
[
485,
24,
1074
],
[
1074,
... | [
[
[
"Pentamidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Pentamidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iodixanol"
],
[
"Iodixanol",
"{u} (Com... | Pentamidine may lead to a major life threatening interaction when taken with Iodixanol and Iodixanol (Compound) resembles Iohexol (Compound)
Pentamidine (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Iohexol (Compound)
Pentamidine may cause a moderate interaction that c... |
DB00712 | DB01028 | 1,274 | 1,332 | [
"DDInter763",
"DDInter1179"
] | Flurbiprofen | Methoxyflurane | Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically p... | An inhalation anesthetic. Currently, methoxyflurane is rarely used for surgical, obstetric, or dental anesthesia. If so employed, it should be administered with nitrous oxide to achieve a relatively light level of anesthesia, and a neuromuscular blocking agent given concurrently to obtain the desired degree of muscular... | Moderate | 1 | [
[
[
1274,
24,
1332
]
],
[
[
1274,
6,
6017
],
[
6017,
45,
1332
]
],
[
[
1274,
24,
1448
],
[
1448,
63,
1332
]
],
[
[
1274,
63,
1512
],
[
151... | [
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methoxyflurane"
]
],
[
[
"Flurbiprofen",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Com... | Flurbiprofen (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Methoxyflurane (Compound)
Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Streptomycin and Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Methoxyflurane
Fl... |
DB00831 | DB00857 | 1,178 | 1,387 | [
"DDInter1866",
"DDInter1768"
] | Trifluoperazine | Terbinafine | A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic. | Terbinafine hydrochloride (Lamisil) is a synthetic allylamine antifungal.[L9065,L9068] It is highly lipophilic in nature and tends to accumulate in skin, nails, and fatty tissues. Like other allylamines, terbinafine inhibits ergosterol synthesis by inhibiting the fungal squalene monooxygenase (also called squalene epox... | Moderate | 1 | [
[
[
1178,
24,
1387
]
],
[
[
1178,
7,
6134
],
[
6134,
45,
1387
]
],
[
[
1178,
6,
7950
],
[
7950,
45,
1387
]
],
[
[
1178,
7,
2473
],
[
2473,... | [
[
[
"Trifluoperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Terbinafine"
]
],
[
[
"Trifluoperazine",
"{u} (Compound) upregulates {v} (Gene)",
"SQLE"
],
[
"SQLE",
"{u} (Gene) is bound by {v}... | Trifluoperazine (Compound) upregulates SQLE (Gene) and SQLE (Gene) is bound by Terbinafine (Compound)
Trifluoperazine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Terbinafine (Compound)
Trifluoperazine (Compound) upregulates RHOA (Gene) and RHOA (Gene) is upregulated by Terbinafine (Compound)
Trifluoper... |
DB00334 | DB00398 | 867 | 79 | [
"DDInter1326",
"DDInter1702"
] | Olanzapine | Sorafenib | Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug inte... | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | Moderate | 1 | [
[
[
867,
24,
79
]
],
[
[
867,
6,
6017
],
[
6017,
45,
79
]
],
[
[
867,
7,
5178
],
[
5178,
46,
79
]
],
[
[
867,
24,
549
],
[
549,
62,
... | [
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
]
],
[
[
"Olanzapine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
... | Olanzapine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Sorafenib (Compound)
Olanzapine (Compound) upregulates XBP1 (Gene) and XBP1 (Gene) is upregulated by Sorafenib (Compound)
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin may... |
DB01175 | DB08824 | 318 | 591 | [
"DDInter672",
"DDInter959"
] | Escitalopram | Ioflupane I-123 | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible ... | Ioflupane (I-123) is a radiopharmaceutical used to image dopamine neurons and diagnose Parkinsonian syndromes. | Moderate | 1 | [
[
[
318,
24,
591
]
],
[
[
318,
6,
2437
],
[
2437,
45,
591
]
],
[
[
318,
21,
29305
],
[
29305,
60,
591
]
],
[
[
318,
64,
401
],
[
401,
... | [
[
[
"Escitalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioflupane I-123"
]
],
[
[
"Escitalopram",
"{u} (Compound) binds {v} (Gene)",
"SLC6A3"
],
[
"SLC6A3",
"{u} (Gene) is bound by {v} (Co... | Escitalopram (Compound) binds SLC6A3 (Gene) and SLC6A3 (Gene) is bound by Ioflupane I-123 (Compound)
Escitalopram (Compound) causes Dysgeusia (Side Effect) and Dysgeusia (Side Effect) is caused by Ioflupane I-123 (Compound)
Escitalopram may lead to a major life threatening interaction when taken with Promethazine and P... |
DB01097 | DB01438 | 1,377 | 585 | [
"DDInter1033",
"DDInter1438"
] | Leflunomide | Phenazopyridine | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Phenazopyridine, also known as Pyridium, is a urinary tract analgesic used for the short-term management of urinary tract irritation and its associated unpleasant symptoms such as burning and pain during urination. In the USA, this drug was previously marked by Roche but has been discontinued by the FDA. It is still us... | Major | 2 | [
[
[
1377,
25,
585
]
],
[
[
1377,
21,
28658
],
[
28658,
60,
585
]
],
[
[
1377,
25,
384
],
[
384,
63,
585
]
],
[
[
1377,
64,
372
],
[
372,
... | [
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phenazopyridine"
]
],
[
[
"Leflunomide",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is caused by {v} ... | Leflunomide (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Phenazopyridine (Compound)
Leflunomide may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Phenazopyridine
L... |
DB00281 | DB12887 | 608 | 1,598 | [
"DDInter1066",
"DDInter1750"
] | Lidocaine | Tazemetostat | Ever since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication. In particular, lidocaine's principal mode of action in acting as a local anesthetic that numbs the sensations of tissues means the agent is indicated for facilitating local anest... | Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Tazemetostat was first named in literature as EPZ-6438. Tazemetaostat was granted FDA approval on 23 January 2020. | Minor | 0 | [
[
[
608,
23,
1598
]
],
[
[
608,
23,
985
],
[
985,
24,
1598
]
],
[
[
608,
24,
1010
],
[
1010,
24,
1598
]
],
[
[
608,
62,
1324
],
[
1324,
... | [
[
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tazemetostat"
]
],
[
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Osimertinib"
],
[
... | Lidocaine may cause a minor interaction that can limit clinical effects when taken with Osimertinib and Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat
Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloq... |
DB01087 | DB01182 | 1,520 | 371 | [
"DDInter1520",
"DDInter1534"
] | Primaquine | Propafenone | An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Ad... | An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated. | Moderate | 1 | [
[
[
1520,
24,
371
]
],
[
[
1520,
63,
847
],
[
847,
1,
371
]
],
[
[
1520,
63,
675
],
[
675,
40,
371
]
],
[
[
1520,
63,
455
],
[
455,
... | [
[
[
"Primaquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propafenone"
]
],
[
[
"Primaquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atomoxetine"
],
[
... | Primaquine may cause a moderate interaction that could exacerbate diseases when taken with Atomoxetine and Atomoxetine (Compound) resembles Propafenone (Compound)
Primaquine may cause a moderate interaction that could exacerbate diseases when taken with Dextropropoxyphene and Dextropropoxyphene (Compound) resembles Pro... |
DB01021 | DB11921 | 674 | 1,019 | [
"DDInter1861",
"DDInter492"
] | Trichlormethiazide | Deflazacort | A thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p830) | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Moderate | 1 | [
[
[
674,
24,
1019
]
],
[
[
674,
24,
959
],
[
959,
24,
1019
]
],
[
[
674,
40,
1326
],
[
1326,
24,
1019
]
],
[
[
674,
1,
359
],
[
359,
... | [
[
[
"Trichlormethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Trichlormethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"... | Trichlormethiazide may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Trichlormethiazide (Compound) resembles Diclofenamide (Compound) and Diclofenamide may cause a moderate i... |
DB01601 | DB08881 | 833 | 868 | [
"DDInter1089",
"DDInter1925"
] | Lopinavir | Vemurafenib | Lopinavir is an antiretroviral protease inhibitor used in combination with other antiretrovirals in the treatment of HIV-1 infection. Lopinavir is marketed and administered exclusively in combination with [ritonavir] - this combination, first marketed by Abbott under the brand name Kaletra in 2000, is necessary due to ... | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Major | 2 | [
[
[
833,
25,
868
]
],
[
[
833,
6,
8374
],
[
8374,
45,
868
]
],
[
[
833,
54,
19133
],
[
19133,
15,
868
]
],
[
[
833,
63,
480
],
[
480,
... | [
[
[
"Lopinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
]
],
[
[
"Lopinavir",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Vemurafe... | Lopinavir (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Lopinavir (Compound) is included by P-Glycoprotein Inhibitors (Pharmacologic Class) and P-Glycoprotein Inhibitors (Pharmacologic Class) includes Vemurafenib (Compound)
Lopinavir may cause a moderate interaction that could exac... |
DB00773 | DB01181 | 896 | 1,532 | [
"DDInter702",
"DDInter906"
] | Etoposide | Ifosfamide | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitoti... | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Moderate | 1 | [
[
[
896,
24,
1532
]
],
[
[
896,
5,
11659
],
[
11659,
44,
1532
]
],
[
[
896,
6,
3486
],
[
3486,
45,
1532
]
],
[
[
896,
21,
29209
],
[
29209... | [
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Etoposide",
"{u} (Compound) treats {v} (Disease)",
"testicular cancer"
],
[
"testicular cancer",
"{u} (Disease) i... | Etoposide (Compound) treats testicular cancer (Disease) and testicular cancer (Disease) is treated by Ifosfamide (Compound)
Etoposide (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Ifosfamide (Compound)
Etoposide (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Ifosfamide (... |
DB00202 | DB00595 | 190 | 1,545 | [
"DDInter1716",
"DDInter1374"
] | Succinylcholine | Oxytetracycline | Succinylcholine is a depolarizing skeletal muscle relaxant consisting of two molecules of the endogenous neurotransmitter [acetylcholine] (ACh) linked by their acetyl groups. It has been widely used for over 50 years, most commonly in its chloride salt form, as a means of neuromuscular blockade during intubation and su... | A tetracycline analog isolated from the actinomycete streptomyces rimosus and used in a wide variety of clinical conditions. | Moderate | 1 | [
[
[
190,
24,
1545
]
],
[
[
190,
24,
964
],
[
964,
1,
1545
]
],
[
[
190,
24,
853
],
[
853,
63,
1545
]
],
[
[
190,
24,
1031
],
[
1031,
... | [
[
[
"Succinylcholine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxytetracycline"
]
],
[
[
"Succinylcholine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxycycline"... | Succinylcholine may cause a moderate interaction that could exacerbate diseases when taken with Doxycycline and Doxycycline (Compound) resembles Oxytetracycline (Compound)
Succinylcholine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium chloride and Magnesium chloride may cause ... |
DB00563 | DB08932 | 663 | 1,398 | [
"DDInter1174",
"DDInter1111"
] | Methotrexate | Macitentan | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Macitentan is a dual endothelin receptor antagonist used in the treatment of pulmonary arterial hypertension. It was first approved by the FDA in 2013. Macitentan differs from its predecessor [bosentan] due to its lower risk of hepatotoxicity. | Moderate | 1 | [
[
[
663,
24,
1398
]
],
[
[
663,
6,
1829
],
[
1829,
45,
1398
]
],
[
[
663,
21,
29429
],
[
29429,
60,
1398
]
],
[
[
663,
24,
283
],
[
283,
... | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macitentan"
]
],
[
[
"Methotrexate",
"{u} (Compound) binds {v} (Gene)",
"ALB"
],
[
"ALB",
"{u} (Gene) is bound by {v} (Compound)",
... | Methotrexate (Compound) binds ALB (Gene) and ALB (Gene) is bound by Macitentan (Compound)
Methotrexate (Compound) causes Infestation NOS (Side Effect) and Infestation NOS (Side Effect) is caused by Macitentan (Compound)
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Fedrati... |
DB00353 | DB06764 | 588 | 1,090 | [
"DDInter1187",
"DDInter1788"
] | Methylergometrine | Tetryzoline (ophthalmic) | A homolog of ergonovine containing one more CH2 group. (Merck Index, 11th ed) | Tetryzoline is a member of imidazolines and a carboxamidine. It has a role as a sympathomimetic agent and a nasal decongestant. It is a conjugate base of a tetryzoline(1+). | Major | 2 | [
[
[
588,
25,
1090
]
],
[
[
588,
40,
628
],
[
628,
25,
1090
]
],
[
[
588,
1,
1131
],
[
1131,
25,
1090
]
],
[
[
588,
40,
628
],
[
628,
... | [
[
[
"Methylergometrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tetryzoline"
]
],
[
[
"Methylergometrine",
"{u} (Compound) resembles {v} (Compound)",
"Ergometrine"
],
[
"Ergometrine",
"{u} may lead to a maj... | Methylergometrine may lead to a major life threatening interaction when taken with Tetryzoline
Methylergometrine (Compound) resembles Ergometrine (Compound) and Ergometrine may lead to a major life threatening interaction when taken with Tetryzoline
Methylergometrine (Compound) resembles Methysergide (Compound) and Met... |
DB00687 | DB11817 | 870 | 1,259 | [
"DDInter747",
"DDInter165"
] | Fludrocortisone | Baricitinib | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Major | 2 | [
[
[
870,
25,
1259
]
],
[
[
870,
24,
1274
],
[
1274,
24,
1259
]
],
[
[
870,
63,
598
],
[
598,
24,
1259
]
],
[
[
870,
24,
1129
],
[
1129,
... | [
[
[
"Fludrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
[
... | Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Nabume... |
DB01309 | DB01583 | 1,254 | 624 | [
"DDInter933",
"DDInter1075"
] | Insulin glulisine | Liotrix | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas... | Liotrix is a synthetically derived thyroid hormone replacement preparation. It consists of levothyroxine sodium (thyroxine, T4) and liothyronine sodium (triiodothyronine, T3) in a 4 to 1 ratio by weight. Liotrix was developed when it was believed that serum levels of both T4 and T3 were maintained by direct thyroidal s... | Moderate | 1 | [
[
[
1254,
24,
624
]
],
[
[
1254,
63,
1152
],
[
1152,
1,
624
]
],
[
[
1254,
63,
542
],
[
542,
40,
624
]
],
[
[
1254,
63,
417
],
[
417,
... | [
[
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liotrix"
]
],
[
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liothyronine"
... | Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Liothyronine and Liothyronine (Compound) resembles Liotrix (Compound)
Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Levothyroxine and Levothyroxine (Compound) resembles L... |
DB09052 | DB10316 | 250 | 334 | [
"DDInter220",
"DDInter1248"
] | Blinatumomab | Mumps virus strain B level jeryl lynn live antigen | Blinatumomab is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody formed by the recombinant fusion of an anti-CD3 single-chain variable fragment (scFV) and an anti-CD19 scFV through a short peptide linker.[A254836,L44311] CD3 is an antigen expressed on the surface of T-cells, while CD19 is mostl... | Mumps virus strain B level jeryl lynn live antigen is a live attenuated virus vaccine for subcutenous injection. It is an active immunization against mumps, which is a common childhood disease. | Major | 2 | [
[
[
250,
25,
334
]
],
[
[
250,
64,
1057
],
[
1057,
25,
334
]
],
[
[
250,
63,
629
],
[
629,
25,
334
]
],
[
[
250,
25,
1259
],
[
1259,
... | [
[
[
"Blinatumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Blinatumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
... | Blinatumomab may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen
Blinatumomab may cause a moderate interaction that could exacerbate diseases when taken with Sirolim... |
DB01254 | DB06402 | 1,213 | 1,079 | [
"DDInter484",
"DDInter1756"
] | Dasatinib | Telavancin | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria. MRSA is an important pathogen capable of causing hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and skin and sub... | Moderate | 1 | [
[
[
1213,
24,
1079
]
],
[
[
1213,
24,
968
],
[
968,
40,
1079
]
],
[
[
1213,
21,
28680
],
[
28680,
60,
1079
]
],
[
[
1213,
62,
112
],
[
112... | [
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telavancin"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oritavancin"
],
[
... | Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Oritavancin and Oritavancin (Compound) resembles Telavancin (Compound)
Dasatinib (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Telavancin (Compound)
Dasatinib may cause a minor interaction that can limit... |
DB01001 | DB01359 | 688 | 729 | [
"DDInter1632",
"DDInter1417"
] | Salbutamol | Penbutolol | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Penbutolol is a drug in the beta-blocker class used to treat hypertension. Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker. Penbutolol can act as a partial agonist at beta adrenergic receptors, since it is a sympathomimetric drug. Penbutolol also demonstrates high... | Major | 2 | [
[
[
688,
25,
729
]
],
[
[
688,
64,
461
],
[
461,
1,
729
]
],
[
[
688,
1,
11460
],
[
11460,
40,
729
]
],
[
[
688,
36,
699
],
[
699,
4... | [
[
[
"Salbutamol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Penbutolol"
]
],
[
[
"Salbutamol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Timolol"
],
[
"Timolol",
"{u} (Compou... | Salbutamol may lead to a major life threatening interaction when taken with Timolol and Timolol (Compound) resembles Penbutolol (Compound)
Salbutamol (Compound) resembles Bupranolol (Compound) and Bupranolol (Compound) resembles Penbutolol (Compound)
Salbutamol (Compound) resembles Nadolol (Compound) and Salbutamol may... |
DB04948 | DB11978 | 1,084 | 124 | [
"DDInter1083",
"DDInter822"
] | Lofexidine | Glasdegib | Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hyp... | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Moderate | 1 | [
[
[
1084,
24,
124
]
],
[
[
1084,
62,
112
],
[
112,
23,
124
]
],
[
[
1084,
63,
475
],
[
475,
24,
124
]
],
[
[
1084,
24,
1342
],
[
1342,
... | [
[
[
"Lofexidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Lofexidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Lofexidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Lofexidine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphin... |
DB01246 | DB08865 | 820 | 1,593 | [
"DDInter45",
"DDInter448"
] | Alimemazine | Crizotinib | A phenothiazine derivative that is used as an antipruritic. | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Major | 2 | [
[
[
820,
25,
1593
]
],
[
[
820,
6,
8374
],
[
8374,
45,
1593
]
],
[
[
820,
7,
7260
],
[
7260,
46,
1593
]
],
[
[
820,
18,
3616
],
[
3616,
... | [
[
[
"Alimemazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
]
],
[
[
"Alimemazine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Crizo... | Alimemazine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound)
Alimemazine (Compound) upregulates MVD (Gene) and MVD (Gene) is upregulated by Crizotinib (Compound)
Alimemazine (Compound) downregulates CDC45 (Gene) and CDC45 (Gene) is downregulated by Crizotinib (Compound)
Alimemazine (Co... |
DB00065 | DB00959 | 581 | 1,486 | [
"DDInter923",
"DDInter1191"
] | Infliximab | Methylprednisolone | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Major | 2 | [
[
[
581,
25,
1486
]
],
[
[
581,
25,
175
],
[
175,
40,
1486
]
],
[
[
581,
25,
167
],
[
167,
1,
1486
]
],
[
[
581,
24,
303
],
[
303,
4... | [
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylprednisolone"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triamcinolone"
],
[
"Triamcinolone"... | Infliximab may lead to a major life threatening interaction when taken with Triamcinolone and Triamcinolone (Compound) resembles Methylprednisolone (Compound)
Infliximab may lead to a major life threatening interaction when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Methylprednisolone (Compound)
... |
DB00927 | DB09080 | 1,559 | 144 | [
"DDInter712",
"DDInter1331"
] | Famotidine | Olodaterol | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</su... | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Moderate | 1 | [
[
[
1559,
24,
144
]
],
[
[
1559,
23,
1247
],
[
1247,
23,
144
]
],
[
[
1559,
24,
956
],
[
956,
24,
144
]
],
[
[
1559,
63,
695
],
[
695,
... | [
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Famotidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
... | Famotidine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Olodaterol
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Norfloxacin a... |
DB08890 | DB14158 | 16 | 882 | [
"DDInter1069",
"DDInter1211"
] | Linaclotide | Microcrystalline cellulose | Linaclotide is a synthetic 14-amino acid cyclic peptide and first-in-class guanylate cyclase-C (G-CC) agonist.[A260271, L47211] Linaclotide is structurally related to human guanylin and uroguanylin, paracrine peptide hormones that are endogenous activators of GC-C. It is also a homolog of a heat-stable enterotoxin deri... | A polysaccharide with glucose units linked as in CELLOBIOSE. It is the chief constituent of plant fibers, cotton being the purest natural form of the substance. As a raw material, it forms the basis for many derivatives used in chromatography, ion exchange materials, explosives manufacturing, and pharmaceutical prepara... | Minor | 0 | [
[
[
16,
23,
882
]
],
[
[
16,
23,
1662
],
[
1662,
23,
882
]
],
[
[
16,
62,
355
],
[
355,
24,
882
]
],
[
[
16,
23,
1662
],
[
1662,
63,... | [
[
[
"Linaclotide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Microcrystalline cellulose"
]
],
[
[
"Linaclotide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Picosulfuric ... | Linaclotide may cause a minor interaction that can limit clinical effects when taken with Picosulfuric acid and Picosulfuric acid may cause a minor interaction that can limit clinical effects when taken with Microcrystalline cellulose
Linaclotide may cause a minor interaction that can limit clinical effects when taken ... |
DB00471 | DB12332 | 201 | 1,619 | [
"DDInter1242",
"DDInter1626"
] | Montelukast | Rucaparib | Montelukast was first approved for clinical use by the US FDA in 1998 as Merck's brand name Singulair. The medication is a member of the leukotriene receptor antagonist (LTRA) category of drugs.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] Although capable of demonstrating effectiveness, the use of such LTRAs like montel... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
201,
24,
1619
]
],
[
[
201,
24,
112
],
[
112,
23,
1619
]
],
[
[
201,
63,
556
],
[
556,
24,
1619
]
],
[
[
201,
24,
1419
],
[
1419,
... | [
[
[
"Montelukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Montelukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Montelukast may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Montelukast may cause a moderate interaction that could exacerbate diseases when taken with Valproic acid an... |
DB00734 | DB08865 | 1,664 | 1,593 | [
"DDInter1605",
"DDInter448"
] | Risperidone | Crizotinib | Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. [Paliperidone], another commonly used SGA, is the primary active metabolite of risperidone (i.e. ... | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Major | 2 | [
[
[
1664,
25,
1593
]
],
[
[
1664,
6,
8374
],
[
8374,
45,
1593
]
],
[
[
1664,
21,
30045
],
[
30045,
60,
1593
]
],
[
[
1664,
24,
283
],
[
28... | [
[
[
"Risperidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
]
],
[
[
"Risperidone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Crizo... | Risperidone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound)
Risperidone (Compound) causes Dizziness postural (Side Effect) and Dizziness postural (Side Effect) is caused by Crizotinib (Compound)
Risperidone may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB00983 | DB01591 | 480 | 667 | [
"DDInter776",
"DDInter1696"
] | Formoterol | Solifenacin | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major ... | Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily. Solifenacin was granted FDA approval on 19 November 2004. | Moderate | 1 | [
[
[
480,
24,
667
]
],
[
[
480,
21,
28743
],
[
28743,
60,
667
]
],
[
[
480,
24,
774
],
[
774,
63,
667
]
],
[
[
480,
63,
1324
],
[
1324,
... | [
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Solifenacin"
]
],
[
[
"Formoterol",
"{u} (Compound) causes {v} (Side Effect)",
"Atrial fibrillation"
],
[
"Atrial fibrillation",
"{u} ... | Formoterol (Compound) causes Atrial fibrillation (Side Effect) and Atrial fibrillation (Side Effect) is caused by Solifenacin (Compound)
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Degarelix and Degarelix may cause a moderate interaction that could exacerbate diseases when... |
DB01390 | DB06212 | 1,117 | 165 | [
"DDInter1683",
"DDInter1833"
] | Sodium bicarbonate | Tolvaptan | Sodium bicarbonate is a white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions. | Tolvaptan is used to treat low blood sodium levels (hyponatremia) associated with various conditions like congestive heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormones (SIADH). FDA approved on May 19, 2009. | Moderate | 1 | [
[
[
1117,
24,
165
]
],
[
[
1117,
21,
28981
],
[
28981,
60,
165
]
],
[
[
1117,
24,
594
],
[
594,
63,
165
]
],
[
[
1117,
24,
478
],
[
478,
... | [
[
[
"Sodium bicarbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolvaptan"
]
],
[
[
"Sodium bicarbonate",
"{u} (Compound) causes {v} (Side Effect)",
"Renal impairment"
],
[
"Renal impairment",
... | Sodium bicarbonate (Compound) causes Renal impairment (Side Effect) and Renal impairment (Side Effect) is caused by Tolvaptan (Compound)
Sodium bicarbonate may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib may cause a moderate interaction that could exacerbate disea... |
DB01068 | DB01205 | 1,565 | 1,404 | [
"DDInter411",
"DDInter748"
] | Clonazepam | Flumazenil | A benzodiazepine used to treat various seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop.[FDA Label][L5572,F3763,F3787,F3796] The agent has also been indicated for treating panic disorder.[FDA Label][A175438,L5572,F3763,F3787,F3796] The mechan... | Fumazenil is an imidazobenzodiazepine derivative and a potent benzodiazepine receptor antagonist that competitively inhibits the activity at the benzodiazepine recognition site on the GABA/benzodiazepine receptor complex, thereby reversing the effects of benzodiazepine on the central nervous system. | Moderate | 1 | [
[
[
1565,
24,
1404
]
],
[
[
1565,
6,
6506
],
[
6506,
45,
1404
]
],
[
[
1565,
21,
29003
],
[
29003,
60,
1404
]
],
[
[
1565,
40,
1382
],
[
1... | [
[
[
"Clonazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flumazenil"
]
],
[
[
"Clonazepam",
"{u} (Compound) binds {v} (Gene)",
"GABRG2"
],
[
"GABRG2",
"{u} (Gene) is bound by {v} (Compound)",... | Clonazepam (Compound) binds GABRG2 (Gene) and GABRG2 (Gene) is bound by Flumazenil (Compound)
Clonazepam (Compound) causes Aggression (Side Effect) and Aggression (Side Effect) is caused by Flumazenil (Compound)
Clonazepam (Compound) resembles Midazolam (Compound) and Midazolam may cause a moderate interaction that cou... |
DB08899 | DB11757 | 129 | 960 | [
"DDInter649",
"DDInter994"
] | Enzalutamide | Istradefylline | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Istradefylline, or KW6002, was developed by Kyowa Hakko Kirin in Japan for the treatment of Parkinson's disease as an adjunct to standard therapy. Unlike standard dopaminergic therapies for Parkinson's, Istradefylline targets adenosine A<sub>2A</sub> receptors in the basal ganglia. This region of the brain is highly in... | Major | 2 | [
[
[
129,
25,
960
]
],
[
[
129,
25,
1135
],
[
1135,
23,
960
]
],
[
[
129,
63,
77
],
[
77,
24,
960
]
],
[
[
129,
25,
1499
],
[
1499,
2... | [
[
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Istradefylline"
]
],
[
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
... | Enzalutamide may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Istradefylline
Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin and Idarubicin may ca... |
DB01098 | DB14730 | 14 | 1,412 | [
"DDInter1622",
"DDInter264"
] | Rosuvastatin | Calaspargase pegol | Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin... | Asparaginase is an important agent used to treat acute lymphoblastic leukemia (ALL) . Asparagine is incorporated into most proteins, and the synthesis of proteins is stopped when asparagine is absent, which inhibits RNA and DNA synthesis, resulting in a halt in cellular proliferation. This forms the basis of asparagina... | Moderate | 1 | [
[
[
14,
24,
1412
]
],
[
[
14,
24,
1439
],
[
1439,
24,
1412
]
],
[
[
14,
63,
322
],
[
322,
24,
1412
]
],
[
[
14,
64,
1668
],
[
1668,
... | [
[
[
"Rosuvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Rosuvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ipilimumab"
... | Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab and Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Epirubici... |
DB00188 | DB09330 | 168 | 985 | [
"DDInter222",
"DDInter1352"
] | Bortezomib | Osimertinib | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Minor | 0 | [
[
[
168,
23,
985
]
],
[
[
168,
24,
112
],
[
112,
23,
985
]
],
[
[
168,
24,
134
],
[
134,
24,
985
]
],
[
[
168,
63,
66
],
[
66,
24,
... | [
[
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Osimertinib"
]
],
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
... | Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and ... |
DB00938 | DB06204 | 455 | 768 | [
"DDInter1635",
"DDInter1746"
] | Salmeterol | Tapentadol | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Tapentadol is a centrally-acting synthetic analgesic with a dual mechanism of action. It is a mu-opioid receptor agonist that also inhibits norepinephrine reuptake.[A260721, A36596] Tapentadol was first approved by the FDA on November 20, 2008. The extended-release formulation of tapentadol was also approved by the FDA... | Moderate | 1 | [
[
[
455,
24,
768
]
],
[
[
455,
21,
28692
],
[
28692,
60,
768
]
],
[
[
455,
24,
1148
],
[
1148,
24,
768
]
],
[
[
455,
63,
874
],
[
874,
... | [
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tapentadol"
]
],
[
[
"Salmeterol",
"{u} (Compound) causes {v} (Side Effect)",
"Mental disorder"
],
[
"Mental disorder",
"{u} (Side Eff... | Salmeterol (Compound) causes Mental disorder (Side Effect) and Mental disorder (Side Effect) is caused by Tapentadol (Compound)
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when ta... |
DB00682 | DB00685 | 126 | 1,299 | [
"DDInter1951",
"DDInter1887"
] | Warfarin | Trovafloxacin | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective again... | Major | 2 | [
[
[
126,
25,
1299
]
],
[
[
126,
25,
872
],
[
872,
40,
1299
]
],
[
[
126,
64,
1467
],
[
1467,
40,
1299
]
],
[
[
126,
24,
328
],
[
328,
... | [
[
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trovafloxacin"
]
],
[
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gemifloxacin"
],
[
"Gemifloxacin",
"{u... | Warfarin may lead to a major life threatening interaction when taken with Gemifloxacin and Gemifloxacin (Compound) resembles Trovafloxacin (Compound)
Warfarin may lead to a major life threatening interaction when taken with Enoxacin and Enoxacin (Compound) resembles Trovafloxacin (Compound)
Warfarin may cause a moderat... |
DB00938 | DB06788 | 455 | 1,616 | [
"DDInter1635",
"DDInter864"
] | Salmeterol | Histrelin | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-con... | Moderate | 1 | [
[
[
455,
24,
1616
]
],
[
[
455,
63,
1664
],
[
1664,
24,
1616
]
],
[
[
455,
24,
623
],
[
623,
24,
1616
]
],
[
[
455,
24,
927
],
[
927,
... | [
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
],
[
... | Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Histrelin
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine and Queti... |
DB00500 | DB00945 | 24 | 1,479 | [
"DDInter1831",
"DDInter20"
] | Tolmetin | Acetylsalicylic acid | A non-steroidal anti-inflammatory agent (anti-inflammatory agents, NON-steroidal) similar in mode of action to indomethacin. | Also known as _Aspirin_, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial... | Moderate | 1 | [
[
[
24,
24,
1479
]
],
[
[
24,
6,
10522
],
[
10522,
45,
1479
]
],
[
[
24,
10,
11666
],
[
11666,
49,
1479
]
],
[
[
24,
54,
19122
],
[
19122,... | [
[
[
"Tolmetin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
]
],
[
[
"Tolmetin",
"{u} (Compound) binds {v} (Gene)",
"PTGS1"
],
[
"PTGS1",
"{u} (Gene) is bound by {v} (Compoun... | Tolmetin (Compound) binds PTGS1 (Gene) and PTGS1 (Gene) is bound by Acetylsalicylic acid (Compound)
Tolmetin (Compound) palliates osteoarthritis (Disease) and osteoarthritis (Disease) is palliated by Acetylsalicylic acid (Compound)
Tolmetin (Compound) is included by Nonsteroidal Anti-inflammatory Compounds (Pharmacolog... |
DB01169 | DB06595 | 57 | 1,491 | [
"DDInter120",
"DDInter1214"
] | Arsenic trioxide | Midostaurin | Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of danger... | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Major | 2 | [
[
[
57,
25,
1491
]
],
[
[
57,
62,
112
],
[
112,
23,
1491
]
],
[
[
57,
64,
888
],
[
888,
24,
1491
]
],
[
[
57,
24,
657
],
[
657,
63,
... | [
[
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Midostaurin"
]
],
[
[
"Arsenic trioxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Arsenic trioxide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Arsenic trioxide may lead to a major life threatening interaction when taken with Tamoxifen and Tamoxif... |
DB08880 | DB11817 | 1,510 | 1,259 | [
"DDInter1771",
"DDInter165"
] | Teriflunomide | Baricitinib | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Major | 2 | [
[
[
1510,
25,
1259
]
],
[
[
1510,
23,
1193
],
[
1193,
23,
1259
]
],
[
[
1510,
62,
1461
],
[
1461,
23,
1259
]
],
[
[
1510,
64,
1274
],
[
12... | [
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
]
],
[
[
"Teriflunomide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Z... | Teriflunomide may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Baricitinib
Teriflunomide may cause a minor interaction that can limit clinical effects when taken with Vitamin E an... |
DB09154 | DB13257 | 1,475 | 260 | [
"DDInter1686",
"DDInter727"
] | Sodium citrate | Ferrous sulfate anhydrous | Sodium citrate is the sodium salt of citric acid. It is white, crystalline powder or white, granular crystals, slightly deliquescent in moist air, freely soluble in water, practically insoluble in alcohol. Like citric acid, it has a sour taste. From the medical point of view, it is used as alkalinizing agent. It works ... | Iron deficiency anemia is a large public health concern worldwide, especially in young children, infants, and women of childbearing age. This type of anemia occurs when iron intake, iron stores, and iron loss do not adequately support the formation of erythrocytes, also known as red blood cells. Ferrous sulfate is a sy... | Moderate | 1 | [
[
[
1475,
24,
260
]
],
[
[
1475,
63,
1096
],
[
1096,
23,
260
]
],
[
[
1475,
63,
1620
],
[
1620,
24,
260
]
],
[
[
1475,
64,
115
],
[
115,
... | [
[
[
"Sodium citrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous sulfate anhydrous"
]
],
[
[
"Sodium citrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Myco... | Sodium citrate may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Ferrous sulfate anhydrous
Sodium citrate may cause a moderate interaction that could exacerbate diseases wh... |
DB00030 | DB01203 | 1,685 | 699 | [
"DDInter934",
"DDInter1255"
] | Insulin human | Nadolol | Human Insulin, also known as Regular Insulin, is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mel... | Nadolol is a nonselective beta adrenal receptor blocker that is used to lower blood pressure.[L7922,L7925] Nonselective beta adrenal receptor blockers may no longer be first line in the treatment of hypertension as newer generations of beta adrenal receptor blockers have higher selectivity and offer better rates of adv... | Moderate | 1 | [
[
[
1685,
24,
699
]
],
[
[
1685,
24,
887
],
[
887,
1,
699
]
],
[
[
1685,
24,
1152
],
[
1152,
23,
699
]
],
[
[
1685,
24,
609
],
[
609,
... | [
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nadolol"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pindolol"
],
[
... | Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Pindolol and Pindolol (Compound) resembles Nadolol (Compound)
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Liothyronine and Liothyronine may cause a minor interaction that can l... |
DB09208 | DB12839 | 934 | 919 | [
"DDInter1410",
"DDInter1411"
] | Pegloticase | Pegvaliase | Pegloticase is a porcine recombinant PEGylated uricase indicated for the treatment of chronic gout in adult patients that do not respond to other types of therapies. Pegloticase has a similar activity to rasburicase, an enzyme that metabolizes uric acid to allantoin. In gout patients treated with pegloticase, the conve... | Pegvaliase is a recombinant phenylalanine ammonia lyase (PAL) enzyme derived from _Anabaena variabilis_ that converts phenylalanine to ammonia and _trans_-cinnamic acid . Both the U.S. Food and Drug Administration and European Medicines Agency approved pegvaliase-pqpz in May 2018 for the treatment of adult patients wit... | Moderate | 1 | [
[
[
934,
24,
919
]
],
[
[
934,
63,
1257
],
[
1257,
24,
919
]
],
[
[
934,
63,
1257
],
[
1257,
24,
268
],
[
268,
24,
919
]
],
[
[
934,
... | [
[
[
"Pegloticase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegvaliase"
]
],
[
[
"Pegloticase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegfilgrastim"
],
... | Pegloticase may cause a moderate interaction that could exacerbate diseases when taken with Pegfilgrastim and Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Pegvaliase
Pegloticase may cause a moderate interaction that could exacerbate diseases when taken with Pegfilgrastim... |
DB00501 | DB00749 | 752 | 59 | [
"DDInter380",
"DDInter699"
] | Cimetidine | Etodolac | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | Etodolac is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. Its therapeutic effects are due to its ability to inhibit prostaglandin synthesis. It is indicated for relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. | Minor | 0 | [
[
[
752,
23,
59
]
],
[
[
752,
6,
6017
],
[
6017,
45,
59
]
],
[
[
752,
21,
29093
],
[
29093,
60,
59
]
],
[
[
752,
63,
245
],
[
245,
2... | [
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Etodolac"
]
],
[
[
"Cimetidine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
... | Cimetidine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Etodolac (Compound)
Cimetidine (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Etodolac (Compound)
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride... |
DB00489 | DB08884 | 17 | 796 | [
"DDInter1704",
"DDInter800"
] | Sotalol | Gadoxetic acid | Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventric... | Gadoxetic acid (gadoxetate) is a paramagnetic gadolinium-containing ionic linear contrast agent in which its salt form, gadoxetate disodium, is used for intravenous injection. Ethoxybenzyl diethylenetriaminepentaacetic acid is the moiety that chelates with a gadolinium ion and forms a stable complex with it to make up ... | Moderate | 1 | [
[
[
17,
24,
796
]
],
[
[
17,
63,
457
],
[
457,
1,
796
]
],
[
[
17,
24,
1106
],
[
1106,
1,
796
]
],
[
[
17,
21,
28841
],
[
28841,
60,... | [
[
[
"Sotalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadoxetic acid"
]
],
[
[
"Sotalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadodiamide"
],
[
... | Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Gadodiamide and Gadodiamide (Compound) resembles Gadoxetic acid (Compound)
Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Gadofosveset trisodium and Gadofosveset trisodium (Compound) resemble... |
DB00285 | DB06605 | 1,100 | 1,409 | [
"DDInter1927",
"DDInter108"
] | Venlafaxine | Apixaban | Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, [desvenlafaxine], works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorde... | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Moderate | 1 | [
[
[
1100,
24,
1409
]
],
[
[
1100,
6,
10215
],
[
10215,
45,
1409
]
],
[
[
1100,
21,
29666
],
[
29666,
60,
1409
]
],
[
[
1100,
25,
1593
],
[
... | [
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
]
],
[
[
"Venlafaxine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)... | Venlafaxine (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Apixaban (Compound)
Venlafaxine (Compound) causes Melaena (Side Effect) and Melaena (Side Effect) is caused by Apixaban (Compound)
Venlafaxine may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a... |
DB00476 | DB08816 | 109 | 578 | [
"DDInter608",
"DDInter1802"
] | Duloxetine | Ticagrelor | Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval... | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Moderate | 1 | [
[
[
109,
24,
578
]
],
[
[
109,
21,
28646
],
[
28646,
60,
578
]
],
[
[
109,
63,
1578
],
[
1578,
24,
578
]
],
[
[
109,
24,
868
],
[
868,
... | [
[
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Duloxetine",
"{u} (Compound) causes {v} (Side Effect)",
"Unspecified disorder of skin and subcutaneous tissue"
],
[
"U... | Duloxetine (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect) and Unspecified disorder of skin and subcutaneous tissue (Side Effect) is caused by Ticagrelor (Compound)
Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Lepirudin and Lepirudin may... |
DB00388 | DB13928 | 1,636 | 1,385 | [
"DDInter1453",
"DDInter1660"
] | Phenylephrine | Semaglutide | Phenylephrine is an alpha-1 adrenergic receptor agonist used to treat hypotension,[L9416,L9410] dilate the pupil, and induce local vasoconstriction. The action of phenylephrine, or neo-synephrine, was first described in literature in the 1930s. Phenylephrine was granted FDA approval in 1939. | Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity.[A31421,L8681] Other members of this drug class include [Exenatide] and [Liraglutide]. Semaglutide was developed by Novo Nordisk and approved ... | Moderate | 1 | [
[
[
1636,
24,
1385
]
],
[
[
1636,
23,
1399
],
[
1399,
63,
1385
]
],
[
[
1636,
63,
73
],
[
73,
24,
1385
]
],
[
[
1636,
24,
1144
],
[
1144,
... | [
[
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Phenylephrine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lithium carbonate"
... | Phenylephrine may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate and Lithium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Ph... |
DB00060 | DB00853 | 912 | 1,686 | [
"DDInter947",
"DDInter1762"
] | Interferon beta-1a | Temozolomide | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | Refractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV) are primary malignant brain tumours with poor prognosis and limited treatment options. Despite considerable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alky... | Moderate | 1 | [
[
[
912,
24,
1686
]
],
[
[
912,
24,
556
],
[
556,
23,
1686
]
],
[
[
912,
24,
1419
],
[
1419,
24,
1686
]
],
[
[
912,
24,
637
],
[
637,
... | [
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Temozolomide"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valproic ... | Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Valproic acid and Valproic acid may cause a minor interaction that can limit clinical effects when taken with Temozolomide
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with... |
DB00285 | DB00738 | 1,100 | 485 | [
"DDInter1927",
"DDInter1420"
] | Venlafaxine | Pentamidine | Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, [desvenlafaxine], works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorde... | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Moderate | 1 | [
[
[
1100,
24,
485
]
],
[
[
1100,
6,
12523
],
[
12523,
45,
485
]
],
[
[
1100,
21,
29002
],
[
29002,
60,
485
]
],
[
[
1100,
23,
112
],
[
112... | [
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
]
],
[
[
"Venlafaxine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound... | Venlafaxine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Pentamidine (Compound)
Venlafaxine (Compound) causes Azotaemia (Side Effect) and Azotaemia (Side Effect) is caused by Pentamidine (Compound)
Venlafaxine may cause a minor interaction that can limit clinical effects when taken with Metronidazole an... |
DB11718 | DB15093 | 927 | 1,654 | [
"DDInter640",
"DDInter1698"
] | Encorafenib | Somapacitan | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Somapacitan, also known as NNC0195-0092, is a growth hormone analog indicated to treat adults with growth hormone deficiency.[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. Somapacitan wa... | Moderate | 1 | [
[
[
927,
24,
1654
]
],
[
[
927,
63,
1135
],
[
1135,
24,
1654
]
],
[
[
927,
25,
351
],
[
351,
24,
1654
]
],
[
[
927,
64,
1468
],
[
1468,
... | [
[
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[
... | Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Encorafenib may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause... |
DB08860 | DB08889 | 788 | 350 | [
"DDInter1479",
"DDInter299"
] | Pitavastatin | Carfilzomib | Pitavastatin, also known as the brand name product Livalo, is a lipid-lowering drug belonging to the statin class of medications. By inhibiting the endogenous production of cholesterol within the liver, statins lower abnormal cholesterol and lipid levels and ultimately reduce the risk of cardiovascular disease. More sp... | Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combi... | Moderate | 1 | [
[
[
788,
24,
350
]
],
[
[
788,
6,
4973
],
[
4973,
45,
350
]
],
[
[
788,
7,
6154
],
[
6154,
45,
350
]
],
[
[
788,
21,
28762
],
[
28762,
... | [
[
[
"Pitavastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
]
],
[
[
"Pitavastatin",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound... | Pitavastatin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Carfilzomib (Compound)
Pitavastatin (Compound) upregulates PSMB9 (Gene) and PSMB9 (Gene) is bound by Carfilzomib (Compound)
Pitavastatin (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Carfilzomib (Compound)
Pitavas... |
DB00197 | DB11978 | 1,324 | 124 | [
"DDInter1881",
"DDInter822"
] | Troglitazone | Glasdegib | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Moderate | 1 | [
[
[
1324,
24,
124
]
],
[
[
1324,
24,
1135
],
[
1135,
23,
124
]
],
[
[
1324,
24,
466
],
[
466,
62,
124
]
],
[
[
1324,
24,
79
],
[
79,
... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[
... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darol... |
DB09481 | DB14491 | 460 | 428 | [
"DDInter1113",
"DDInter725"
] | Magnesium carbonate | Ferrous fumarate | Magnesium carbonate, also known as magnesite, is a common over the counter remedy for heartburn and upset stomach caused by overproduction of acid in the stomach [FDA Label]. | Used in treatment of iron deficiency anemia. | Moderate | 1 | [
[
[
460,
24,
428
]
],
[
[
460,
63,
1096
],
[
1096,
23,
428
]
],
[
[
460,
62,
752
],
[
752,
23,
428
]
],
[
[
460,
63,
1008
],
[
1008,
... | [
[
[
"Magnesium carbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous fumarate"
]
],
[
[
"Magnesium carbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Myc... | Magnesium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Ferrous fumarate
Magnesium carbonate may cause a minor interaction that can limit clinical effects whe... |
DB00081 | DB00975 | 273 | 1,317 | [
"DDInter1838",
"DDInter573"
] | Tositumomab | Dipyridamole | Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues). It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine). | A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752) | Major | 2 | [
[
[
273,
25,
1317
]
],
[
[
273,
23,
944
],
[
944,
62,
1317
]
],
[
[
273,
25,
714
],
[
714,
63,
1317
]
],
[
[
273,
24,
318
],
[
318,
... | [
[
[
"Tositumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dipyridamole"
]
],
[
[
"Tositumomab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile... | Tositumomab may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Dipyridamole
Tositumomab may lead to a major life threatening interaction when taken with Iloprost and Iloprost may cause a mode... |
DB00501 | DB00726 | 752 | 1,164 | [
"DDInter380",
"DDInter1876"
] | Cimetidine | Trimipramine | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. | Moderate | 1 | [
[
[
752,
24,
1164
]
],
[
[
752,
24,
1237
],
[
1237,
40,
1164
]
],
[
[
752,
63,
576
],
[
576,
40,
1164
]
],
[
[
752,
62,
216
],
[
216,
... | [
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimipramine"
]
],
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
],
... | Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine and Clomipramine (Compound) resembles Trimipramine (Compound)
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Methadone and Methadone (Compound) resembles Trimipramine (Comp... |
DB00957 | DB08904 | 873 | 375 | [
"DDInter1314",
"DDInter342"
] | Norgestimate | Certolizumab pegol | Norgestimate was first described in the literature in 1977. It was developed by Ortho Pharmaceutical Corporation as part of an effort to develop new hormonal contraceptives with reduced adverse effects. It is commonly formulated with [ethinylestradiol] as a combined oral contraceptive that can also be used to treat mod... | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Moderate | 1 | [
[
[
873,
24,
375
]
],
[
[
873,
40,
1336
],
[
1336,
24,
375
]
],
[
[
873,
23,
14
],
[
14,
24,
375
]
],
[
[
873,
63,
58
],
[
58,
24,
... | [
[
[
"Norgestimate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Norgestimate",
"{u} (Compound) resembles {v} (Compound)",
"Etonogestrel"
],
[
"Etonogestrel",
"{u} may... | Norgestimate (Compound) resembles Etonogestrel (Compound) and Etonogestrel may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Norgestimate may cause a minor interaction that can limit clinical effects when taken with Rosuvastatin and Rosuvastatin may cause a moderate inte... |
DB08871 | DB11003 | 36 | 748 | [
"DDInter666",
"DDInter100"
] | Eribulin | Anthrax vaccine | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for... | Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to *Bacillus anthracis*. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsula... | Moderate | 1 | [
[
[
36,
24,
748
]
],
[
[
36,
63,
322
],
[
322,
24,
748
]
],
[
[
36,
25,
676
],
[
676,
63,
748
]
],
[
[
36,
24,
1619
],
[
1619,
63,
... | [
[
[
"Eribulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Eribulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
... | Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Eribulin may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may c... |
DB01072 | DB09098 | 915 | 98 | [
"DDInter129",
"DDInter1700"
] | Atazanavir | Somatrem | Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses p... | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Moderate | 1 | [
[
[
915,
24,
98
]
],
[
[
915,
63,
608
],
[
608,
23,
98
]
],
[
[
915,
25,
159
],
[
159,
63,
98
]
],
[
[
915,
64,
11
],
[
11,
24,
... | [
[
[
"Atazanavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Atazanavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
... | Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Somatrem
Atazanavir may lead to a major life threatening interaction when taken with Larotrectinib and Larotrectinib may cause ... |
DB04865 | DB06616 | 4 | 594 | [
"DDInter1335",
"DDInter224"
] | Omacetaxine mepesuccinate | Bosutinib | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Moderate | 1 | [
[
[
4,
24,
594
]
],
[
[
4,
63,
883
],
[
883,
1,
594
]
],
[
[
4,
18,
2035
],
[
2035,
45,
594
]
],
[
[
4,
7,
8686
],
[
8686,
45,
... | [
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib (Compound) resembles Bosutinib (Compound)
Omacetaxine mepesuccinate (Compound) downregulates IRAK1 (Gene) and IRAK1 (Gene) is bound by Bosutinib (Compound)
Omacetaxine mepesuccinate (Compoun... |
DB00631 | DB06186 | 372 | 1,439 | [
"DDInter405",
"DDInter969"
] | Clofarabine | Ipilimumab | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex. Ipilimumab was granted FDA approva... | Moderate | 1 | [
[
[
372,
24,
1439
]
],
[
[
372,
63,
912
],
[
912,
24,
1439
]
],
[
[
372,
24,
1412
],
[
1412,
63,
1439
]
],
[
[
372,
24,
267
],
[
267,
... | [
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ipilimumab"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon beta-1a"
]... | Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Cal... |
DB00055 | DB00682 | 834 | 126 | [
"DDInter605",
"DDInter1951"
] | Drotrecogin alfa | Warfarin | Drotrecogin alfa is activated human protein C that is synthesized by recombinant DNA technology. It is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and a light chain linked by a disulfide bond. Drotrecogin alfa was withdrawn from the market after a major study indicated th... | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Major | 2 | [
[
[
834,
25,
126
]
],
[
[
834,
23,
944
],
[
944,
62,
126
]
],
[
[
834,
25,
477
],
[
477,
62,
126
]
],
[
[
834,
24,
1100
],
[
1100,
2... | [
[
[
"Drotrecogin alfa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
]
],
[
[
"Drotrecogin alfa",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Cha... | Drotrecogin alfa may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Warfarin
Drotrecogin alfa may lead to a major life threatening interaction when taken with Cilostazol and Cilostazol may ca... |
DB11057 | DB11978 | 720 | 124 | [
"DDInter1223",
"DDInter822"
] | Mineral oil | Glasdegib | Mineral oil, or paraffin oil, is a mixture of higher alkanes from a mineral source, such as petroleum. Petroleum mineral oil is manufactured from crude oils by vacuum distillation to produce several distillates and a residual oil that are then further refined. During the modern refining process, aromatics are reduced b... | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Moderate | 1 | [
[
[
720,
24,
124
]
],
[
[
720,
63,
1079
],
[
1079,
24,
124
]
],
[
[
720,
24,
180
],
[
180,
63,
124
]
],
[
[
720,
24,
1612
],
[
1612,
... | [
[
[
"Mineral oil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Mineral oil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telavancin"
],
[
... | Mineral oil may cause a moderate interaction that could exacerbate diseases when taken with Telavancin and Telavancin may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Mineral oil may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine and Olic... |
DB00987 | DB08827 | 1,224 | 990 | [
"DDInter460",
"DDInter1085"
] | Cytarabine | Lomitapide | A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant p... | Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R). | Major | 2 | [
[
[
1224,
25,
990
]
],
[
[
1224,
6,
8374
],
[
8374,
45,
990
]
],
[
[
1224,
24,
1362
],
[
1362,
63,
990
]
],
[
[
1224,
24,
77
],
[
77,
... | [
[
[
"Cytarabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomitapide"
]
],
[
[
"Cytarabine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Lomitap... | Cytarabine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lomitapide (Compound)
Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Lomitapide
Cytarabine may cause a... |
DB00414 | DB09154 | 590 | 1,475 | [
"DDInter16",
"DDInter1686"
] | Acetohexamide | Sodium citrate | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | Sodium citrate is the sodium salt of citric acid. It is white, crystalline powder or white, granular crystals, slightly deliquescent in moist air, freely soluble in water, practically insoluble in alcohol. Like citric acid, it has a sour taste. From the medical point of view, it is used as alkalinizing agent. It works ... | Minor | 0 | [
[
[
590,
23,
1475
]
],
[
[
590,
24,
1603
],
[
1603,
23,
1475
]
],
[
[
590,
24,
22
],
[
22,
24,
1475
]
],
[
[
590,
25,
1539
],
[
1539,
... | [
[
[
"Acetohexamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium citrate"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Captopril"
],
... | Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Captopril and Captopril may cause a minor interaction that can limit clinical effects when taken with Sodium citrate
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine and E... |
DB00816 | DB01182 | 1,674 | 371 | [
"DDInter1346",
"DDInter1534"
] | Orciprenaline | Propafenone | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated. | Moderate | 1 | [
[
[
1674,
24,
371
]
],
[
[
1674,
63,
847
],
[
847,
1,
371
]
],
[
[
1674,
25,
772
],
[
772,
40,
371
]
],
[
[
1674,
64,
1523
],
[
1523,
... | [
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propafenone"
]
],
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atomoxetine"
],
... | Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Atomoxetine and Atomoxetine (Compound) resembles Propafenone (Compound)
Orciprenaline may lead to a major life threatening interaction when taken with Carvedilol and Carvedilol (Compound) resembles Propafenone (Compound)
Orcip... |
DB00845 | DB09078 | 1,490 | 1,228 | [
"DDInter406",
"DDInter1036"
] | Clofazimine | Lenvatinib | Clofazimine is a highly lipophilic antimicrobial riminophenazine dye used in combination with other agents, such as [dapsone], for the treatment of leprosy. It was originally described in 1957 and was the prototypical riminophenazine dye - a bright-red dye that, in its clinical use, results in long-lasting discoloratio... | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progressi... | Moderate | 1 | [
[
[
1490,
24,
1228
]
],
[
[
1490,
23,
112
],
[
112,
23,
1228
]
],
[
[
1490,
24,
609
],
[
609,
24,
1228
]
],
[
[
1490,
24,
603
],
[
603,
... | [
[
[
"Clofazimine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Clofazimine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[... | Clofazimine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lenvatinib
Clofazimine may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin an... |
DB00694 | DB01033 | 51 | 328 | [
"DDInter485",
"DDInter1156"
] | Daunorubicin | Mercaptopurine | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | Moderate | 1 | [
[
[
51,
24,
328
]
],
[
[
51,
5,
11555
],
[
11555,
44,
328
]
],
[
[
51,
6,
16392
],
[
16392,
45,
328
]
],
[
[
51,
21,
28681
],
[
28681,
... | [
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mercaptopurine"
]
],
[
[
"Daunorubicin",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u}... | Daunorubicin (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Mercaptopurine (Compound)
Daunorubicin (Compound) binds XDH (Gene) and XDH (Gene) is bound by Mercaptopurine (Compound)
Daunorubicin (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effe... |
DB00377 | DB09020 | 1,494 | 28 | [
"DDInter1382",
"DDInter212"
] | Palonosetron | Bisacodyl | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first... | Bisacodyl, a diphenylmethane derivative, is a commonly used over the counter stimulant laxative for occasional constipation.[A233300,L13362] Both bisacodyl and [picosulfate] are metabolized to the same active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM).[A233290,A233300,A207700] Bisacodyl was patented on 2... | Moderate | 1 | [
[
[
1494,
24,
28
]
],
[
[
1494,
21,
28666
],
[
28666,
60,
28
]
],
[
[
1494,
24,
739
],
[
739,
24,
28
]
],
[
[
1494,
25,
540
],
[
540,
... | [
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
],
[
[
"Palonosetron",
"{u} (Compound) causes {v} (Side Effect)",
"Nervous system disorder"
],
[
"Nervous system disorder",
... | Palonosetron (Compound) causes Nervous system disorder (Side Effect) and Nervous system disorder (Side Effect) is caused by Bisacodyl (Compound)
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Lomefloxacin and Lomefloxacin may cause a moderate interaction that could exacerba... |
DB00413 | DB00486 | 1,346 | 1,614 | [
"DDInter1505",
"DDInter1253"
] | Pramipexole | Nabilone | Pramipexole is a drug used to treat the symptoms of Parkinson's Disease (PD). It is a _non-ergot dopamine agonist_ drug that is efficacious in treating various Parkinson's symptoms such as tremor, rigidity, and bradykinesia (slow movement). It was first approved by the FDA in 1997. Parkinson's Disease is one of the mos... | Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and... | Moderate | 1 | [
[
[
1346,
24,
1614
]
],
[
[
1346,
24,
530
],
[
530,
1,
1614
]
],
[
[
1346,
21,
28789
],
[
28789,
60,
1614
]
],
[
[
1346,
63,
999
],
[
999,... | [
[
[
"Pramipexole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
]
],
[
[
"Pramipexole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
],
[
... | Pramipexole may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol (Compound) resembles Nabilone (Compound)
Pramipexole (Compound) causes Loss of consciousness (Side Effect) and Loss of consciousness (Side Effect) is caused by Nabilone (Compound)
Pramipexole may cause ... |
DB00026 | DB05679 | 1,184 | 1,683 | [
"DDInter94",
"DDInter1907"
] | Anakinra | Ustekinumab | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta.... | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Moderate | 1 | [
[
[
1184,
24,
1683
]
],
[
[
1184,
23,
1461
],
[
1461,
23,
1683
]
],
[
[
1184,
23,
1193
],
[
1193,
62,
1683
]
],
[
[
1184,
24,
1042
],
[
10... | [
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
],
[
[
"Anakinra",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
"V... | Anakinra may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Ustekinumab
Anakinra may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconat... |
DB00056 | DB08913 | 816 | 1,186 | [
"DDInter814",
"DDInter1561"
] | Gemtuzumab ozogamicin | Radium Ra 223 dichloride | Gemtuzumab ozogamicin is a recombinant humanized IgG4 kappa antibody which is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora ssp. calichensis. Gemtuzumab ozogamicin has approximately 50% of the antibody loaded with 4-6 moles calicheami... | Radium Ra 223 Dichloride is a radiopharmaceutical containing the radioisotope radium-223 that emits short range but high linear energy alpha particles. As a cation, radium mimics calicum and binds to hydroxyapatite, which is a bone mineral found in areas of high bone turnover as seen in bone metastases. It was first ap... | Moderate | 1 | [
[
[
816,
24,
1186
]
],
[
[
816,
24,
372
],
[
372,
24,
1186
]
],
[
[
816,
24,
1362
],
[
1362,
63,
1186
]
],
[
[
816,
25,
1377
],
[
1377,
... | [
[
[
"Gemtuzumab ozogamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
]
],
[
[
"Gemtuzumab ozogamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}"... | Gemtuzumab ozogamicin may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride
Gemtuzumab ozogamicin may cause a moderate interaction that could exacerbate diseases... |
DB00283 | DB00490 | 701 | 946 | [
"DDInter395",
"DDInter254"
] | Clemastine | Buspirone | An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness. | Buspirone is a novel anxiolytic agent with a unique structure and a pharmacological profile. Belonging to the azaspirodecanedione drug class, buspirone is a serotonin 5-HT<sub>1A</sub> receptor agonist that is not chemically or pharmacologically related to benzodiazepines, barbiturates, and other sedative/anxiolytic dr... | Moderate | 1 | [
[
[
701,
24,
946
]
],
[
[
701,
6,
8374
],
[
8374,
45,
946
]
],
[
[
701,
21,
29209
],
[
29209,
60,
946
]
],
[
[
701,
35,
1242
],
[
1242,
... | [
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Buspirone"
]
],
[
[
"Clemastine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Clemastine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Buspirone (Compound)
Clemastine (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Buspirone (Compound)
Clemastine (Compound) resembles Cetirizine (Compound) and Clemastine may cause a moderate interaction that could e... |
DB00675 | DB04844 | 888 | 843 | [
"DDInter1744",
"DDInter1778"
] | Tamoxifen | Tetrabenazine | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008. | Moderate | 1 | [
[
[
888,
24,
843
]
],
[
[
888,
24,
479
],
[
479,
40,
843
]
],
[
[
888,
6,
12523
],
[
12523,
45,
843
]
],
[
[
888,
21,
28698
],
[
28698,
... | [
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetrabenazine"
]
],
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[
... | Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil (Compound) resembles Tetrabenazine (Compound)
Tamoxifen (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Tetrabenazine (Compound)
Tamoxifen (Compound) causes Insomnia (Side Effect) and Insomnia ... |
DB00865 | DB09038 | 939 | 1,450 | [
"DDInter187",
"DDInter636"
] | Benzphetamine | Empagliflozin | A sympathomimetic agent with properties similar to dextroamphetamine. It is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222) | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Moderate | 1 | [
[
[
939,
24,
1450
]
],
[
[
939,
24,
659
],
[
659,
63,
1450
]
],
[
[
939,
63,
1179
],
[
1179,
24,
1450
]
],
[
[
939,
24,
688
],
[
688,
... | [
[
[
"Benzphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Benzphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
],... | Benzphetamine may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Benzphetamine may cause a moderate interaction that could exacerbate diseases when taken with Insulin lisp... |
DB00580 | DB12267 | 311 | 1,476 | [
"DDInter1910",
"DDInter233"
] | Valdecoxib | Brigatinib | Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke. | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
311,
24,
1476
]
],
[
[
311,
25,
629
],
[
629,
24,
1476
]
],
[
[
311,
24,
123
],
[
123,
24,
1476
]
],
[
[
311,
24,
1421
],
[
1421,
... | [
[
[
"Valdecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Valdecoxib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",... | Valdecoxib may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Exenatide and Exenatide may cause a mo... |
DB00637 | DB09078 | 1,557 | 1,228 | [
"DDInter128",
"DDInter1036"
] | Astemizole | Lenvatinib | Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progressi... | Moderate | 1 | [
[
[
1557,
24,
1228
]
],
[
[
1557,
23,
112
],
[
112,
23,
1228
]
],
[
[
1557,
63,
1100
],
[
1100,
24,
1228
]
],
[
[
1557,
24,
938
],
[
938,
... | [
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Astemizole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Astemizole may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lenvatinib
Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and Ven... |
DB06717 | DB11921 | 875 | 1,019 | [
"DDInter778",
"DDInter492"
] | Fosaprepitant | Deflazacort | Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Major | 2 | [
[
[
875,
25,
1019
]
],
[
[
875,
63,
959
],
[
959,
24,
1019
]
],
[
[
875,
24,
1619
],
[
1619,
63,
1019
]
],
[
[
875,
24,
98
],
[
98,
... | [
[
[
"Fosaprepitant",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
]
],
[
[
"Fosaprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glip... | Fosaprepitant may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Fosaprepitant may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Ru... |
DB00333 | DB01169 | 576 | 57 | [
"DDInter1166",
"DDInter120"
] | Methadone | Arsenic trioxide | Methadone is a potent synthetic analgesic that works as a full µ-opioid receptor (MOR) agonist and N-methyl-d-aspartate (NMDA) receptor antagonist. As a full MOR agonist, methadone mimics the natural effects of the body's opioids, endorphins, and enkephalins through the release of neurotransmitters involved in pain tra... | Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of danger... | Major | 2 | [
[
[
576,
25,
57
]
],
[
[
576,
6,
8374
],
[
8374,
45,
57
]
],
[
[
576,
23,
112
],
[
112,
23,
57
]
],
[
[
576,
24,
603
],
[
603,
63,
... | [
[
[
"Methadone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Methadone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Ars... | Methadone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Arsenic trioxide (Compound)
Methadone may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Arsenic trioxide
Methad... |
DB00092 | DB01229 | 58 | 973 | [
"DDInter40",
"DDInter1377"
] | Alefacept | Paclitaxel | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intr... | Moderate | 1 | [
[
[
58,
24,
973
]
],
[
[
58,
24,
310
],
[
310,
63,
973
]
],
[
[
58,
24,
134
],
[
134,
24,
973
]
],
[
[
58,
23,
1461
],
[
1461,
24,
... | [
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
... | Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinor... |
DB01177 | DB08899 | 77 | 129 | [
"DDInter904",
"DDInter649"
] | Idarubicin | Enzalutamide | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
77,
24,
129
]
],
[
[
77,
63,
918
],
[
918,
1,
129
]
],
[
[
77,
6,
12523
],
[
12523,
45,
129
]
],
[
[
77,
7,
5562
],
[
5562,
46,
... | [
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
],
... | Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide (Compound) resembles Enzalutamide (Compound)
Idarubicin (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Enzalutamide (Compound)
Idarubicin (Compound) upregulates LOXL1 (Gene) and LOXL1 (... |
DB00712 | DB00884 | 1,274 | 1,008 | [
"DDInter763",
"DDInter1604"
] | Flurbiprofen | Risedronic acid | Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically p... | Risedronic acid is a third generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease[FDA Label][A959,A203111]. It functions by preventing resorption of bone[FDA Label]. | Moderate | 1 | [
[
[
1274,
24,
1008
]
],
[
[
1274,
63,
1485
],
[
1485,
1,
1008
]
],
[
[
1274,
6,
7720
],
[
7720,
45,
1008
]
],
[
[
1274,
21,
28931
],
[
289... | [
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risedronic acid"
]
],
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alendronic acid"
... | Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Alendronic acid and Alendronic acid (Compound) resembles Risedronic acid (Compound)
Flurbiprofen (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is bound by Risedronic acid (Compound)
Flurbiprofen (Compound) causes Haemorrhage (... |
DB06772 | DB08901 | 310 | 1,468 | [
"DDInter259",
"DDInter1492"
] | Cabazitaxel | Ponatinib | Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more ... | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Moderate | 1 | [
[
[
310,
24,
1468
]
],
[
[
310,
63,
478
],
[
478,
24,
1468
]
],
[
[
310,
6,
3486
],
[
3486,
45,
1468
]
],
[
[
310,
21,
29024
],
[
29024,
... | [
[
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
],
[
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
... | Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Cabazitaxel (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Ponatinib (Compound)
Cabazitaxel (Compoun... |
DB09030 | DB09075 | 840 | 498 | [
"DDInter1945",
"DDInter621"
] | Vorapaxar | Edoxaban | Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). By inhibiting PAR-1, a thrombin receptor expr... | Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to r... | Major | 2 | [
[
[
840,
25,
498
]
],
[
[
840,
23,
944
],
[
944,
62,
498
]
],
[
[
840,
63,
41
],
[
41,
24,
498
]
],
[
[
840,
24,
321
],
[
321,
63,
... | [
[
[
"Vorapaxar",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Edoxaban"
]
],
[
[
"Vorapaxar",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile",
... | Vorapaxar may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Edoxaban
Vorapaxar may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran and Levomilnaci... |
DB00039 | DB06616 | 1,253 | 594 | [
"DDInter1380",
"DDInter224"
] | Palifermin | Bosutinib | Palifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli. Palifermin was granted FDA approval on 15 December 2004. | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Moderate | 1 | [
[
[
1253,
24,
594
]
],
[
[
1253,
24,
663
],
[
663,
24,
594
]
],
[
[
1253,
24,
1619
],
[
1619,
63,
594
]
],
[
[
1253,
24,
985
],
[
985,
... | [
[
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
[
... | Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Ruca... |
DB00612 | DB01001 | 1,121 | 688 | [
"DDInter216",
"DDInter1632"
] | Bisoprolol | Salbutamol | Bisoprolol is a cardioselective β1-adrenergic blocking agent used to treat high blood pressure.[A180472,L7219] It is considered a potent drug with a long-half life that can be used once daily to reduce the need for multiple doses of antihypertensive drugs. Bisoprolol is generally well tolerated, likely due to its β1-ad... | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Moderate | 1 | [
[
[
1121,
24,
688
]
],
[
[
1121,
24,
874
],
[
874,
24,
688
]
],
[
[
1121,
63,
1636
],
[
1636,
24,
688
]
],
[
[
1121,
24,
1148
],
[
1148,
... | [
[
[
"Bisoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
]
],
[
[
"Bisoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epinephrine"
],
[
... | Bisoprolol may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine and Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol
Bisoprolol may cause a moderate interaction that could exacerbate diseases when taken with Phenylephrine and P... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.